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UNDERSTANDING PATIENT EXPERIENCES WITH EPILEPSY 
MONITORING DURING THE COVID-19 PANDEMIC 
BRIANNA BAILEY 
ABSTRACT 
Background:   Epilepsy monitoring units (EMUs) provide a safe environment for 
forming a more illustrative understanding of the patient’s seizure disorder.  Patients are 
admitted to EMUs usually for several days at a time.  Upon admission, 
electroencephalogram (EEG) electrodes are placed and patients are continuously watched 
via EEG, video, and audio means.  By weaning patients off anti-epileptic medications and 
monitoring brain activity with EEGs, the data will typically allow for a stronger 
appreciation of the seizure activity.  Therefore, it will provide information to develop a 
more targeted clinical approach for the patient.   
Objective:   The purpose of the study is to gain a better understanding of patients’ 
expectations and experiences with being monitored for seizure activity in an EMU, 
especially during the Coronavirus Disease 2019 (COVID-19) pandemic 
Methods:   Patients were interviewed with regards to their inpatient EMU admission for 
continuous EEG monitoring at Beth Israel Deaconess Medical Center (BIDMC).  Phone 
interviews were conducted both before and after the EMU admission for each patient, 
using a structured questionnaire that focused on topics such as proclaimed knowledge of 
personal seizure disorder, quality of life, EMU experience, and hospital admission during 




exploratory manner to identify relevant themes.  The study was conducted according to a 
protocol approved by the BIDMC Committee on Clinical Investigations. 
Results:   From September 2020 through December 2020, 15 patients were enrolled and 
interviewed (11 female; age range 26-68 years [median 48]; length of stay range 2-12 
days [median 5]). The majority of the population was admitted for event capture or 
seizure characterization (13/15) and had a history of seizure activity (14/15) The majority 
of patients had a history of focal seizures (12).  Only 4/15 patients had a family history of 
seizures.    Overall, patients felt extremely comfortable speaking with providers.  A third 
(4/12) did not have any notable negative experiences.  There were no overarching 
patterns to the negative experiences that were reported; most responses were specific to 
the individual.  The vast majority (83.3%) applauded providers and staff involved in their 
EMU admission.   
Conclusions:   Despite the COVID-19 pandemic, epilepsy patients had mostly positive 
experiences with their EMU hospitalization at BIDMC.  Continuous EEG monitoring 
remains an important aspect of clinical epilepsy evaluation for some patients, and was a 
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 Epilepsy is most often characterized by visible seizure activity.  Seizures are 
merely a symptom of epilepsy.  Rather, epilepsy is better defined as a dynamic disorder.  
Seizure activity itself is clinically defined by atypical hypersynchronous discharge of a 
network of cortical neurons.  Isolated seizures, non-epileptic seizures, are traditionally 
triggered by acute systemic or neurological insult.  Therapy for isolated seizures is 
defined by the direct cause of the seizure and does not warrant epileptic interventions like 
antiepileptic drugs (AEDs) (Bromfield 2006).  For example, severe hypoglycemia may 
result in an isolated seizure.  The response would be to treat the hypoglycemia which will 
indirectly stop further seizure activity (England 2012).   
Epileptic seizures differ in that the cause cannot be traced to a source, labeling 
these seizures as spontaneous.  General seizure activity qualifies as epileptic if there are 
two unprovoked seizures outside of 24 hours.  Epilepsy is a spectrum of disorders 
presenting in over 25 different forms.  The disorder can be categorized by seizure type 
and syndromes.  Seizures may be excessive neuronal discharges that are widespread or 
focused.  The type of seizure is determined to be focal, where it is limited to one 
hemisphere, or generalized, where it crosses hemispheres (England 2012). 
 A single seizure usually lasts between seconds to minutes without requiring 
medical intervention.  Status epilepticus is an extreme seizure activity which is 
characterized by prolonged seizing without recovering from the postictal state in between 
episodes.  The individual will remain in this state for more than five minutes and require 




result from several different sources.  Bromfield et. al (2006) categorizes the causes by, 
“increased excitatory synaptic neurotransmission, decreased inhibitory 
neurotransmission, an alteration in voltage gated ion channels, or an alteration of intra- or 
extracellular ion concentrations in favor of membrane depolarization.”   
Within the cerebral cortex exists two main types of cells.  The principal neuron 
cells are responsible for projecting information to neurons of distant areas in the brain.  
These cells are commonly excitatory synapses on postsynaptic neurons.  Interneurons 
function within local-circuit cells, where they are able to direct activity of neighboring 
neurons.  These cells are commonly inhibitory synapses on principal neurons or other 
inhibitory neurons.  Activity of principal neuron cells and interneurons are regulated by 
recurrent inhibition, which acts as part of negative feedback loops (Bromfield 2006). 
 Acute complications of epilepsy result from the possible collapse and uncontrolled 
movement throughout the body.  Collapse from seizing is uncontrolled and frequently 
will result in trauma to the head or other parts of the body.  This depends on where and 
how the individual falls.  Other acute injuries include biting down on the tongue and/or 
lip.  Complications of chronic seizures may result in cognitive deficits, mental illness, 
and co-occurrence of somatic diseases such as sleep disorders, migraines, or 
cardiovascular disease (England 2012).  The comorbidities associated with epilepsy are 
more impactful on the health of the individual than the physical seizure itself.  Psychiatric 
comorbidities are heavily focused on by clinicians, for epileptic patients are twice as 
likely to develop major depressive disorder compared to others.  In response, traditional 




pharmaceuticals.  The exact correlation between epilepsy and risk of depression is not 
well described.  Therefore, the comorbidity of depression is treated directly. Other 
comorbidities include complications in general physical health and reproductive health 
(Chang 2020). 
 
Types of Seizures 
The physical manifestation of a seizure is not a disease.  Rather, it is the symptom 
of dysregulated neurological activity.  Collectively, epileptic episodes are associated with 
three main features.  This includes an aura, which is a sensation that acts as a warning 
sign right before the onset of a seizure.  Common auras present as visual changes, an 
odor, or a noise.  A second feature is loss of consciousness.  This occurs on a spectrum as 
an individual may a fixed gaze or completely collapse.  The third feature is the motor 
component.  This can vary from lip smacking, to general shaking, to violent convulsions.  
Both focal and generalized seizure have these three features.  However, the specifics vary 
by the type of seizure activity. 
Epileptic seizures are classified into two major types.  Although a patient may 
predominantly experience a specific type of seizure activity, this does not limit the patient 
from experiencing other types of seizures.  Partial (or focal) seizures describe seizure 
activity originating from one cerebral hemisphere.  This is further classified by 
consciousness and generalized convulsions.  Simple partial seizures do not involve an 




evolve to secondary generalized seizures, which involve seizure activity progressing 
across the hemispheres (Panayiotopoulos 2005).  
Generalized seizures describe seizure activity occurring across both hemispheres.  
Primarily generalized seizure activity begins bilateral.  Conversely, secondarily 
generalized seizures begin in a localized area a partial seizure.  Generalized seizures are 
further described by uncontrolled muscle movements.  Absence seizures are generalized 
seizures that begin with a staring spell and are most common in adolescents.  Children 
typically grow out of these seizures and do not need continued medical management into 
adulthood.  Atonic seizures are more abrupt and associated with a sudden drop in muscle 
tone.  Myoclonic seizures are associated with sudden uncontrolled jolting movements.  
This results from an increase in muscle tone.  Tonic seizures involve muscle stiffening 
and a loss of consciousness.  Clonic seizures include muscle spasms and jerk movements.  
Tonic and clonic seizure activity may be experienced together as a generalized tonic-





Figure 1: Illustrations of physical manifestations of seizure activity.  Seizure activity 
and seizure symptoms are defined by two major categories, partial and generalized.  
These categories are further subdivided based on the three features of seizures, aura, loss 
of consciousness, and the motor component (emDOCs). 
 
GABA Receptors 
The GABAA receptor is a transmembrane receptor composed of five subunits.  
The subunits come together in a circular fashion forming around a central pore.  It is an 
ionotropic receptor that serves as a ligand-gated ion channel to the inhibitory 
neurotransmitter gamma-aminobutyric acid (GABA).  Within the cell, GABA acts in an 
inhibitory mechanism to prevent action potentials from firing within the neuron.  This is 
valuable when neurons are overexcited, such as with anxiety.  When this system is unable 




uncontrollably.  Depending on the location, this can result in anxiety and epilepsy (Farb 
2014). 
GABAB receptors are linked to G-proteins, formed by seven transmembrane 
domains.  Instead of creating a pore, like GABAA receptors, they use secondary 
messenger systems via G-proteins to carry out their messages.  GABAB receptors are 
predominantly found in the prefrontal cortex where they regulate higher order thinking. 
GABAB receptors act very slowly to inhibit the secondary messenger system associated 
with adenylate cyclase.  Consequently, this reduces the amount of GABA released since 
the adenylate cyclase cascade is halted.  GABAB receptors are located presynaptically 
where they function as autoreceptors to regulate release of neurotransmitters including 
GABA and post synaptically where they regulate activity of downstream neurons.  
GABAB receptors function by two means, autoreceptors and heteroreceptors.  
Autoreceptors regulate the release of GABA.  By this mechanism, the GABAB receptor 
inhibits the adenylate cyclase cascade of the G-protein.  Thus, GABA release is reduced.  
Heteroreceptors inhibit the protein kinase C cascade of the G-protein which instead 
inhibits release of neurotransmitters other than GABA (Farb 2014).  
 
Pharmacological Interventions 
 The therapeutic goal of AEDs is to control seizures in a patient.  Unfortunately, 
AEDs do not cure epilepsy, but they do bring balance to the inherent instability of the 
brain during seizure activity.  When developing a pharmacological plan for patients, the 




compliance and the greatest quality of life.  In epileptic patients, the neuronal activity is 
viewed as dysregulated plasticity.  The focus pharmacologic therapeutics is to restore 
balance of inhibition and excitation.  A large fraction of patients have seizure disorders 
linked to genetic mutations in the GABA receptors.  Therefore, most AEDs attempt to 
balance the excitatory neurotransmitters, like glutamate, with the inhibitory 
neurotransmitters, like GABA (Rogawski 2004).   
 The mechanism of action of AEDs can be broken down into three classes (Figure 
2).  Once class of drugs restores balance by increasing GABA transmission.  Vigabatrin 
is a GABA analogue which inhibits the breakdown of GABA.  This occurs by 
irreversibly inhibiting GABA transaminase (GABA-T), the enzyme responsible for 
GABA breakdown.  This therapeutic has a long half-life and does not induce p450 
enzymes.  Therefore, it is ideal for patients receiving polypharmaceutical therapy.  The 
p450 enzymes are a major class of enzymes involved in Phase I biotransformation of 
pharmaceutics.  Valproate is a reversible GABA-T inhibitory and is the drug of choice 
for myoclonic seizures in adolescents.  However, valproate is known to affect other parts 
of the body such as inhibiting histone deacetylase.  As well, it is associated with 
hepatotoxicity and is biotransformed by glucuronide conjugation.  Therefore, it is 
impacted by the p450 enzymes and is not always ideal for polypharmacy.  Tiagabine is an 
alternative agent for partial epilepsy.  It functions as a selective GABA reuptake 
inhibitor, thereby causing more GABA to remain in the synapse.  By consequence, it 
lengthens the effects of GABA.  Common side effects include confusion, difficulty 




be ideal in combination with other drugs.  Topiramate is an alternative agent for 
generalized and partial seizures.  It is known to work at multiple receptors resulting in 
increased GABAergic transmission and a decreased glutamate transmission.  Excitatory 
glutamate pathways have decreased activity due to topiramate blocking voltage-gated 
sodium channels, thus increasing the refractory period between synapses.  Levetiracetam 
is commonly used for myoclonic epilepsy.  It is highly selective and is not dependent on 
the p450 enzymes for metabolism (Rogawski 2004).  GABA transmission is enhanced by 
promoting the fusing of vesicles to the membrane of the postsynaptic terminal to then be 
released into the synaptic cleft. 
 A second class of AEDs reduce seizure activity by blocking voltage-gated sodium 
channels.  As a result, action potentials are blocked or delayed by a longer refractory 
period.  Common genetic mutations resulting in epilepsy cause the shortening of the 
inactivation state of action potentials.  These drugs work to correct this imbalance.  For 
example, phenytoin slows the rate of recovery of sodium channels, thus lengthen the 
refractory period.  It is predominately prescribed for tonic-clonic seizure activity, but also 
is an alternative drug for partial seizures.  Carbamazepine has the same mechanism of 
action as phenytoin, but is ideal for partial seizures.  It is used as an alternative for tonic-
clonic seizures.  Lamotrigine is known to inactivate sodium channels.  It is commonly 
prescribed for partial and myoclonic seizures.  Compliance is typically high with this 
drug, as it is not metabolized in the liver.  Therefore, patients do not need routine blood 
monitoring.  A small percent of users experience a life-threatening skin rash.  In patients 




seen to be higher with generic forms of lamotrigine.  Valproate is also included in this 
class as it prolongs sodium channel activation in addition to acting as a reversible GABA-
T inhibitory (Rogawski 2004).   
 A third class of AEDs primarily function by reducing calcium flow through t-type 
channels.  These channels are found in the thalamus.  Dysfunction of calcium t-type 
channels is characteristic of absence seizures.  Absence seizures are a type of generalized 
epilepsy common in children and are often outgrown.  Seizure activity is generated by 
burst firing of action potentials that are the result of low-frequency stimulation of the 
midline thalamic structures.  Valproate is also included in this class, as it is known to 
inhibit t-type channels.  Ethosuximide also inhibits t-type calcium channels and is 
frequently prescribed to children with absence seizures.  It has a very long half-life of 53 
hours, making it easier for this population to comply.  Also, it lacks hepatotoxicity.  
However, 80% of ethosuximide undergoes hepatic metabolism (Rogawski 2004).  
Nevertheless, the benefits outweigh the costs and is the drug of choice for pediatrics with 






Figure 2: Summary of target sites of various AEDs.  Synaptic transmission is initiated 
by an action potential.  To begin, the voltage-gated sodium open and the cell depolarizes.  
As a consequence of the action potential, the vesicles full of neurotransmitters are 
released.  The vesicle binds to the cell membrane and releases the neurotransmitters into 
the synaptic cleft.  The neurotransmitter then binds to the associated receptor on the 
postsynaptic membrane.  GABAergic, inhibitory, transmission is depicted on the left.  
Glutaminergic, excitatory, transmission is depicted on the right (Schmidt 2014).  Calcium 
t-type channels are not depicted in the image.  These are specific to the thalamus. 
 
Electroencephalography 
 Electroencephalography (EEG) is used to monitor the electrical activity of the 
brain.  It is an external device composed of either plastic or metal electrodes.  These are 






Figure 3: Electroencephalogram electrodes.  Noninvasive EEG electrodes are placed 
directly on the scalp based on a specific pattern around anatomical landmarks.  These 
plastic or metal discs are precisely placed and usually attached with paste (Mayo Clinic). 
 
The fundamentals of EEG records are based on measuring the electrical-potential 
difference between two points on the surface of the scalp (Vander 1990).  The electrodes 
send the electrical impulses detected in the brain to a recording machine.  These impulses 
are translated into visual wave patterns which can then be analyzed by a clinician 
(Freeman 2012).  Seizure activity appears as distinct spikes in the wave pattern with high 
amplitudes, as depicted in Figure 3 (Vander 1990).  Monitoring often includes video and 
audio recording to record any outward indicators of seizure activity.  EEG is effective in 
diagnosing, monitoring, and managing seizure activity (Kulkarni 2013).  Monitoring in 
this way is regularly used due to noninvasive recording, high temporal resolution, and 





Figure 3: EEG recording of generalized spikes.  In a generalized seizure, spike wave 
discharges present on the EEG recording.  These are seen in the middle of the image, 
where the waves have notably large amplitudes.  Spike-wave complexes are caused by 
simultaneous active spread across the cortical areas (Bromfield 2006).   
 
Mental Health Comorbidities 
 Mental health conditions are historically one of the most common comorbidities 
associated with epilepsy.  These conditions frequently include depression, anxiety, 
attention deficit hyperactivity disorder, and psychosis.  Initially thought to be a side effect 
of AEDs, mental health comorbidities were linked to the challenges of daily life with 
epilepsy.  Individuals with epilepsy often report their medical condition as very impactful 




epilepsy and mental health conditions.  An individual with one puts them at greater risk 
for developing the other.  In the case of depression, it has been found to lower the seizure 
threshold, thus putting the individual at a higher risk for developing epilepsy.  
Conversely, individuals with poor prognosis of seizures or limited control over seizure 
activity, are found to be at a higher risk for depression (England 2012). 
 
Epilepsy Monitoring Units 
 Epilepsy monitoring units (EMUs) provide a safe environment for forming a more 
illustrative understanding of the patient’s seizure disorder.  Patients are admitted to 
EMUs usually for several days at a time.  Upon admission, EEG electrodes are placed 
and patients are continuously watched via EEG, video, and audio means.  By weaning 
patients off anti-epileptic medications and monitoring brain activity with EEGs, the data 
will typically allow for a stronger appreciation of the seizure activity.  Therefore, it will 
provide information to develop a more targeted clinical approach for the patient.   
 
COVID-19 
 Originating in Wuhan China, the 2019 novel coronavirus hit the United States. in 
late December 2019.  As the Coronavirus Disease 2019 (COVID-19) progressed to a 
pandemic, countries around the world began to shut down.  On March 10th, 2020, 
Massachusetts officially declared a state of emergency.  As a result, all elective 
procedures were canceled, including video-EEG monitoring in EMUs.  Starting in late 




the pandemic continued to go on, it has brought much concern to patients and families.  




SPECIFIC AIMS  
Epilepsy monitoring units (EMUs) are frequently seen in teaching hospitals.  
They allow for a unique hospital experience where patients are withdrawn from anti-
epileptic medications and monitored via continuous EEG, video, and audio means.  At 
Beth Israel Deaconess Medical Center (BIDMC) in Boston, MA, the EMU exists on Farr 
11 with a traditional frequency of about 3-4 patients per week.  The use of EMUs and 
outcomes are well described.  However, the expectations and experiences from the 
patient’s perspective are not.  The purpose of the study is to gain a better understanding 
of patient experiences with regards to seizure disorders, specifically patients in the EMU.  
This procedure/testing is performed outside of the context of the study.  From this 
population, interactions with patients will be limited to mail, email, and phone surveys.   
Conduction of the study will be occurring in the midst of the COVID-19 
pandemic, and therefore will be a major focus when surveying this population.  Patients 
will be surveyed before hospital admission and after discharge, to develop a qualitative 
analysis.  The experience of the patient will be described by his/her:   
Proclaimed knowledge of personal seizure disorder    
Quality of life   
EMU experience   
Hospital admission during the COVID-19 pandemic     
 






Patients were initially contacted by mail, providing an overview of the study and 
requesting consent to part take.  This occurred after the initial scheduling of an EMU 
admission - about 1-2 weeks before.  Interested patients that responded to the letter were 
scheduled for an audio call using the application, Starleaf.  The initial survey occurred 
before admission and would last 30-45 minutes.  7 days after discharge home, patients 
were contacted by email and/or phone to schedule a follow up audio call.  The second 
survey would last about 20-30 minutes. 
  Initial prospective agreement will be assumed when patients reply to the initial 
letter expressing interest in participating in the study.  At this point, the investigator 
performed a medical record review.  This will include collecting information about: 
         Patient demographics 
         Seizure history and clinical characteristics 
         Related medications 
         Related history i.e. Previous TBI 
         Reason for admission to EMU 
         Past visits to EMU 
 
Study population and eligibility criteria 
Epilepsy can present very differently from patient to patient.  The EMU 




patients will have been followed and evaluated by BIDMC and be admitted to the same 
EMU.  Although the specifics of the seizure disorder and outcomes of the study will 
differ from patient to patient, the population will have a relatively consistent experience 
in exploration of their personal seizure disorders.  This study will not be limited outside 
of the described population parameters with regards to age, sex, race/ethnicity, 
occupation status, education, etc. 
 
Statistical Considerations 
The general framework of this study seeks to explore patient experiences in the 
EMU.  The question format of the surveys is designed to be open-ended.  This is to allow 
for a qualitative evaluation once a reasonable sample size has been reached.  The 
objectives of data analysis aim to describe the demographics of the sample, describe and 
explain relationships, describe individual experiences, and to define group norms.  
This study is largely exploratory and descriptive, though our results will allow for 
future studies to address these critical questions in a more quantitative manner.  We do 
plan to assess quantitatively the changes in participants’ responses from before their 
EMU admission to after their EMU admission, in a paired-sample manner.  Fisher exact 
or chi-square tests will be used to compare categorical variables and outcomes (such as 
responses recorded on Likert-type scales).  Paired t-tests, multifactor ANOVA, or non-






The findings of this study will predominantly help with improving the EMU to 
better suit the needs of patients and serve as a means of quality improvement.  In 
addition, this will be the first opportunity to study elective monitoring by these means 
during a pandemic.  Establishing a baseline of patient experiences now will allow for 
more effective quality improvement studies later on.  In addition, it is anticipated that this 
will be one of the first studies interviewing this population during the COVID-19 
pandemic.  From this, it is intended to propagate further research related to the pandemic. 
For the patients participating, this study provides an opportunity to ask questions 
and learn more about the EMU than they otherwise would.  As well, it will allow for 
quality improvement for future EMU admissions and of other patients admitted to the 
EMU.   
 
Possible Risks and Analysis of Risk/Benefit Ratio 
The risk of this study is minimal.  Personal health information (PHI) will be used 
throughout the study.  However, subjects will be de-identified once data analysis begins.  
Potential areas of risk include psychological effects as a result of survey questions 
potentially triggering a negative memory or experience.  The survey questions have been 
designed to be open-ended and generalized, allowing patients the opportunity to share 
only the information that they choose to.  As well, a potential concern of the initial survey 




COVID-19 pandemic. Outside of these potential risks, this is a non-invasive study 
performed over the phone 
 
Recruitment and Consent Procedures 
Patients that are scheduled for observation in the EMU will be contacted by mail 
before their hospital admission.  For patients who are not followed by the Primary 
Investigator, an email will be sent to the primary neurologist for approval to recruit the 
patient (Appendix A).  The letter will describe the study and ask for a response to set up a 
phone meeting via Starleaf (Appendix B).  No other patients with epilepsy will be 
recruited outside of this defined population.  Consent will be assumed for patients who 
respond to the recruitment letter, volunteering to participate in the study.  Prospective 
agreement will be formally secured when scheduling the phone surveys, as well as at the 
beginning of both surveys (Appendix C).  Survey questions are designed to be open-
ended and non-bias.  Patients will be at liberty to disclose as much or as little information 






The 15 patients involved in this study were predominantly female (11/15).  Age 
on admission ranged from 26 to 68 years with a median age of 48 years.  The length of 
stay for patients ranged from 2 to 12 days with a median of 5 days.  The majority of the 
population was admitted for event capture or seizure characterization (13/15) with a 
history of seizure activity (14/15).  Patients were also admitted for medication 
adjustments (3/15) and other, atypical reasons (2/15).  The majority of patients 
experienced focal seizures (12).  Tonic-clonic seizures were the most common 
generalized seizure type in the sample (8/15), with patients also experiencing tonic 
seizures (1/15), clonic seizures (1/15), and myoclonic seizures (1/15).  With respect to all 
seizure types, about half of patients identified known triggers (8/15) and the majority of 
patients reported experiencing auras (9/15).  Only a fraction of patients had a family 
history of seizures (4/15).  Within this group, other common comorbidities included 
hypertension (5/15) and anxiety/depression (6/15). 
In order to analyze patient experiences quantitatively, most questions were asked 
on a ranking scale.  The scales varied from descriptive responses (1 to 5) and numerical 
responses (1 to 10).  The exact scale varied from question, but not between the same 
questions in the initial survey and follow-up survey.  In evaluating descriptive statistics, 
average values were rounded to the nearest whole number.  The various scales are 
described in presented with the questionnaires in Appendix D and E.  Of the 15 patients 
in the sample, not all answered every question.  For questions that not all patients 




Proclaimed knowledge of personal seizure disorder 
Patients were asked to rank their understanding of their seizure disorder both 
before and after their EMU admission.  The ranking system was scaled by the following 
descriptions: very poor (1), poor (2), fair (3), good (4), excellent (5).  With respect to the 
individual, the null hypothesis was rejected as there was a statistically significant change 
in response (critical value: 2.160, t value: 2.639).  Of the sample, 50% (7/14) had no 
change in response, 42.9% (6/14) increased ranking, and 7.1% (1/14) decreased ranking.  
On the same scale, patients were asked to rank their understanding of their current 
treatment regimen, before and after their EMU admission.  Again, the null hypothesis 
was rejected (critical value: 2.160, t value: 2.818), where 57.1% (8/14) patients did not 
change their response, 28.6% (4/14) increased, and 14.3% (2/14) decreased their ranking. 
 
Survey Responses - Proclaimed knowledge of personal seizure disorder   
Topic  EMU admission Mean SD  Mode Median 
Understanding of seizure disorder  

















Understanding of treatment regimen  
(n = 14) 
















Table 1: Survey responses related to questions about knowledge of seizure disorder.  





Quality of life 
Survey Responses - Quality of life 
Topic  Mean  SD  Mode  Median  
















Table 2: Survey responses related to questions about quality of life.  Prior to 
admission, patients were asked to rank their quality of life. 
 
EMU experience 
Patients were asked to rank their comfort level of speaking with providers both 
before and after their EMU admission.  The ranking system was on the scale of 1 to 10, 
with 1 being not comfortable at all and 10 being extremely comfortable.  With respect to 
the individual, the null hypothesis was accepted as there was not a statistically significant 
change in response (critical value: 2.160, t value: 1.729).  Of the sample, 78.6% (11/14) 
had no change in response, 21.4% (3/14) increased ranking, and no patients decreased 
ranking.  On the same scale, patients were asked to rank their control over their treatment 
plan, before and after their EMU admission.  Conversely, the null hypothesis was rejected 
(critical value: 2.160, t value: 3.489), where 29.4% (5/14) patients did not change their 







Survey Responses - EMU experience 
Topic  EMU admission Mean  SD  Mode Median 
Comfort level speaking with providers 
(n = 14) 
Before  9.27 2.47 10 8 
After   9.57 1.16 10 10 
Control over treatment plan 
(n = 14) 
Before   7.47 2.47 10 8 
After   8.71 1.64 10 10 
Concern about upcoming admission   4.8 3.57 1 4 
Was the process worth it   8.85 1.57 10 10 
Table 3: Survey responses related to questions about EMU experience.  Patients were 
asked a series of questions before admission of their expectations of the EMU.  
Proceeding discharge, patients were asked the same or similar questions to measure 
change in responses.  In addition, patients were asked to rank their concerns about being 
admitted to the EMU.  Following discharge, patients were asked if the process was worth 
it. 
 
Hospital admission during the COVID-19 pandemic 
In reference to the COVID-19 pandemic, patients were asked to rank their 
concern about receiving in-patient medical care on a scale of on a scale of 1 to 10, with 1 
being not concerned at all and 10 being extremely concerned.  With respect to the 
individual, the null hypothesis was rejected as there was a statistically significant change 
in response (critical value: 2.179, t value: 3.203).  Of the sample, 46.2% (6/13) had no 
change in response, 38.5% (5/13) increased ranking, and 15.4% (2/13) decreased ranking.  
Patients were also asked to rank the impact of the limitation of visitors on a scale of 1 to 
10, with 1 being not at all impactful and 10 being extremely impactful.  With respect to 
the individual, the null hypothesis was rejected as there was a statistically significant 




had no change in response, 23.1% (3/13) increased ranking, and 38.5% (5/13) decreased 
ranking.  
Proceeding, patients were asked to rank the importance of the increase in personal 
protective equipment (PPE) of patients and providers on a scale of not at all (1), slightly 
(2), moderately (3), very (4), or extremely (5).  With respect to the individual, the null 
hypothesis was rejected as there was a statistically significant change in response (critical 
value: 2.179, t value: 2.422).  Of the sample, 61.5% (8/13) had no change in response, 
30.1% (4/13) increased ranking, and 7.7% (1/13) decreased ranking.  Lastly, patients 
were asked to rank how informed they were about how the pandemic would affect their 
hospital stay on the same scale.  With respect to the individual, the null hypothesis was 
rejected as there was a statistically significant change in response (critical value: 2.201, t 
value: 2.491).  Of the sample, 58.3% (7/12) had no change in response, 33.3% (4/12) 

















Mean SD Mode Median 












  (2.33) 
1.45 




Concern about receiving in-patient 
medical care during the pandemic 
(n = 13) 
Before 4.07 3.06 1 4 
After 4.69 3.64 1 5 
Limitations on visitors 
(n = 13) 
Before 5.4 4 1 6 
After 5.23 3.83 1 5 
Importance of increase in PPE 

























Informed about impact of COVID-19 
on admission 






























Table 4: Survey response related to questions about in-patient care during the 
COVID-19 pandemic.  Before admission, patients were asked to rank the impact of the 
pandemic on their life as well as to managing their seizure disorder.  Also, Patients were 
asked a series of questions before admission of their expectations of in-patient care 
during the pandemic.  Proceeding discharge, patients were asked the same or similar 
questions to measure change in responses.  As a concluding question, patients were asked 





 The use of EMUs and outcomes are well described.  However, the expectations 
and experiences from the patient’s perspective are not.  The purpose of the study is to 
gain a better understanding of patient experiences with regards to seizure disorders, 
specifically patients in the EMU.  
 
Proclaimed knowledge of personal seizure disorder   
On average, patients initially described their understanding of their seizure 
disorder as “fair”.  After discharge from the EMU, the average response increased their 
response to “good.”  With an overall increase, there was a statistically significant increase 
on the individual level, with 42.86% (6/14) increasing their answer.  More specifically, 
patients described their understanding of their treatment regimen as “good.”  Although 
there was not a significant change in overall response, 28.57 (4/14) patients increased 
their response.  All patients reported a physician as their main source of information for 
their seizure disorder, with 40% (6/15) performing additional research.  
 
Quality of Life  
This population described the impact of their seizure disorder on daily life to be 
“often.”  However, there was an overall low impact of side effects from AEDS.  In 
reflection of their life collectively, 60% (9/15) of patients reported independence as a 
major challenge in living with a seizure disorder.  Included were remarks about not being 




the symptoms of seizure disorders to be a major challenge.  Common symptoms reported 
were fatigue, weakness, dizziness, and poor memory.  However, 73.3% (11/15) spoke of 
significant positive impacts on their life as a whole.  Recurrent themes in patient 
responses were taking better care of self, overall a stronger person, and gained a greater 
appreciation for life.  About a fourth of the patients did not have any positive outcomes to 
report from their experiences.  
 
EMU experience  
Overall, patients felt extremely comfortable speaking with providers.  There was 
not a statistically significant change at the individual level, nor as a group.  The average 
response was 9.27 out of 10 prior to admission, and 9.57 proceeding discharge.  
Contrastingly, there was a significant change with reported control of the patient’s 
treatment plan, with 50% (7/14) increasing their response.  On a scale of 1 to 10, with 1 
being not at all in control and 10 being completely in control, patients reported an 
average of 7.47 before admission.  This increased to an average of 8.71 after discharge 
from the EMU.  When asked about the upcoming admission to the EMU, patients 
reported an intermediate degree of concern.  On a scale of 1 to 10, with 1 being not 
concerned at all and 10 being extremely concerned, the average response was 4.8.   
Only 26.7% (4/15) of patients had previously been admitted to the EMU before.  
Of those who had not experienced the EMU before, 45.5% (5/11) described their 
expectations as anticlimactic.  Common terms used were boring, relaxing, and quiet.  




disorder.  In reflection of their experience, 33.3% (4/12) of patients declined notable 
negative experiences.  For patients who did report negative experiences, there were no 
overarching patterns.  Rather, most responses were specific to the individual.  
Conversely, 83.3% (10/12) applauded providers and staff involved in their EMU 
admission.  In addition, 41.7% (5/12) patients expressed their gratitude for their medical 
treatment and/or overall prognosis.  In summary, patients reported that yes, the process 
was very much worth it.    On a scale of 1 to 10, with 1 being not at all and 10 being 
extremely worth it, the average response was 8.85.  
 
Hospital admission during the COVID-19 pandemic 
Of the total population, 86.67% claimed that neither they nor a household member 
tested positive for COVID-19 prior to admission.  On average, patients reported that the 
pandemic had a moderate effect on their daily life.  More specifically, the impact of the 
pandemic on managing a seizure disorder was described as mild.  With regards to 
receiving in-patient care during the pandemic, patients reported an overall increase in 
concern.  In addition, patients viewed increased PPE as moderately important before their 
admission to very important after discharge.  However, patients responded that the 
actions BIDMC took, to minimize exposure to COVID-19, were far above standards.  As 
well, the impact of the limitation on visitors decreased proceeding discharge.  In general, 
patients proclaimed to be very informed about COVID-19.  Patients responded that they 
were mildly informed about the impact of COVID-19 on in-patient care, which increased 






 Unfortunately, in-patient procedures were limited during the pandemic.  It was 
difficult to recruit patients because the EMU was admitting at about half the rate as 
before the pandemic.  Of the 15 patients, responses to some questions varied greatly.  
With regards to those topics discussed, the responses do not necessarily represent the 
entire population.  Future research about patient experiences in the EMU should be 
targeted for when admissions are at the pre-pandemic rate.  For future research related to 
the COVD-19 pandemic, it would be valuable to interview patients from other elective 
in-patient procedures.  Nonetheless, this study serves as an introduction to patient 






APPENDIX A.  Request of approval from primary neurologist to recruit patient  
 
Hello [name of neurologist], 
  
I hope that you are doing well.   
  
I would like to ask to recruit [name of patient] in a study, conducted by Dr. Bernard Chang, with 
regards to patient experiences in Epilepsy Monitoring Units (EMUs).  Participation in the study 
will involve two phone surveys, one before admission to the EMU and one after discharge.  It 
will take approximately 30 minutes for the first survey and 20 minutes for the second.   
  
Attached to this email is: 
            The recruitment letter 
            Survey questions 
            An overview of the study 
  
I look forward to hearing from you. 
  





APPENDIX B. Recruitment letter 
 
Dear [name of patient], 
 
You are receiving this letter because you are a patient at Beth Israel Deaconess Medical 
Center (BIDMC).  We would like to tell you about a study, conducted by Dr. Bernard 
Chang, with regards to patient experiences in Epilepsy Monitoring Units (EMUs). 
 
Participation in the study will involve two phone surveys, one before admission to the 
EMU and one after discharge.  It will take approximately 30 minutes for the first survey 
and 20 minutes for the second.  It will not cost you anything to be in the study.  If you 
volunteer to participate, before the first survey we will review your medical records to 
collect information about your seizure history. 
 
The risks involved in participating in the study include the risk of breach of 
confidentiality.  However, this risk will be minimized by taking the approach steps to 
securely document necessary personal information behind the BIDMC firewall. We will 
be documenting minimal personal information as to communicate with you throughout 
the study.  Participating in research is voluntary.  Your decision to participate or not 
participate will not affect the care you receive at BIDMC. 
 
If you have questions about the study and are interested in learning more, or would like to 
NOT be contacted further about the study, please contact Brianna Bailey by email at 
bmbailey@bidmc.harvard.edu.  If we do not hear from you in the next 4-7 days, we will 
call you to tell you more about the study. 
 
Included in this letter is a description of the study and the list of questions I will be asking 
if you choose to participate.  Thank you for considering our study.  I look forward to 
hearing from you! 
 






APPENDIX C.  Obtaining prospective agreement scripts 
 
Scheduling Phone Interview 
Thank you for your interest in our research study about patient experiences in Epilepsy 
Monitoring Units.  This study is being conducted by Dr. Bernard Chang at BIDMC and 
you may contact him at bchang@bidmc.harvard.edu or 617.632.8930 for more 
information or if you have any questions about the study or your rights.  
 
The purpose of the study is to gain a better understanding of patient experiences with 
regards to seizure disorders, specifically patients in the EMU. Conduction of the study 
will be occurring in the midst of the COVID-19 pandemic, and therefore will be a major 
focus. You have been invited to participate in this study because of your upcoming 
admission to the EMU at Beth Israel Deaconess Medical Center.  
 
By volunteering to be in the study, you will be interviewed to learn more about your 
seizure disorder, quality of life, EMU experiences, and experience being admitted to the 
hospital during the COVID-19 pandemic. The first interview will last about 30 minutes 
and the second interview will last about 20 minutes. The interviews will take place over 
the phone. You can choose not to answer any of the questions you are asked and can stop 
the interview at any time.  
 
Since you first volunteered for the study, some of your personal information has been 
collected from your medical records, as described in the initial letter you received.  This 
includes information such as your medical record number, seizure history, related 
medications, etc.  We will keep your answers confidential and will not share personal 
information about you with anyone outside the research team.  
 
Being in this study is voluntary. Please contact Brianna at bmbailey@bidmc.harvard.edu 
or at 617.632.8930 with questions about this study. If you have questions about your 
rights participating in research or would like to speak with someone independent from the 
research team, please contact the Human Subject Protection Office (617) 975-8500.  
 
Initial Survey 
At this time, would you be willing to answer questions about your health and medical 
history, as detailed in the letter mailed to you?  
  
I would like to bring to your attention that some of the questions may make you feel 
uncomfortable.  You can stop at any time.  You can skip any questions and retract any 
answers you provide.   
  
I will record your answers in writing, but only collect detailed contact information if you 





The risk of allowing us to record your name with your answers is a loss of 
confidentiality.  We will take reasonable steps to protect the confidentiality of your 
information.   
  
May I begin?   
 
Follow-up Survey 
Thank you for your interest in our research study about patient experiences in Epilepsy 
Monitoring Units.  This study is being conducted by Dr. Bernard Chang at BIDMC and 
you may contact him at bchang@bidmc.harvard.edu for more information or if you have 
any questions about the study or your rights.  
  
At this time, would you be willing to answer questions about your health and medical 
history, as detailed in the letter mailed to you?  
  
I would like to bring to your attention that some of the questions may make you feel 
uncomfortable.  You can stop at any time.  You can skip any questions and retract any 
answers you provide.   
  
I will record your answers in writing and will be removing any personal identifiable 
information at the conclusion of this conversation.   
  




APPENDIX D.  Initial survey 
 
Patient education of seizure disorder 
How would you describe your understanding of your seizure disorder? 
            Very poor, Poor, Fair, Good, or Excellent 
How would you describe your understanding of your current treatment regimen? 
   Very poor, Poor, Fair, Good, or Excellent 
What are your main sources of information/education? 
  
Quality of life 
How frequently does your seizure disorder affect your day-to-day life? 
            Never, Rarely, Sometimes, Often, or Always 
How frequently do the side effects of anti-epileptic medications affect your day-to-day 
life? 
            Never, Rarely, Sometimes, Often, or Always 
What do you struggle with the most as a result of epilepsy? 
What positives came out of this aspect of your life? 
  
EMU quality control 
How comfortable do you feel speaking with healthcare providers and asking questions? 
On a scale of 1 to 10, with 1 being not comfortable at all and 10 being extremely  
 comfortable.  
Do you feel that you have control over your treatment plan? 
On a scale of 1 to 10, with 1 being not at all in control and 10 being completely in           
 control.  
How concerned are you about your upcoming hospital admission in the EMU? 
On a scale of 1 to 10, with 1 being not concerned at all and 10 being extremely 
 concerned.  
For patients staying in the EMU for the first time, 
            What do you anticipate your hospital stay to be like? 
For patients returning to the EMU, 
            What was/were your past stay(s) in the EMU like? 
What do you hope to get out of this process? 
  
COVID 
Have you or a member of your household been diagnosed with COVID? 
To what degree has COVID impacted your day-to-day life? 
            Not at all, Very mildly, Mildly, Moderately, or Severely  
To what degree has COVID impacted your day-to-day management of your seizure 
disorder? 
            Not at all, Very mildly, Mildly, Moderately, or Severely  





On a scale of 1 to 10, with 1 being not concerned at all and 10 being extremely 
 concerned.  
What are your major concerns? 
How does the limitation on visitors impact your upcoming admission to the EMU? 
On a scale of 1 to 10, with 1 being not at all and 10 being extremely impactful. 
How important to you is the increase in personal protective equipment of patients and 
providers? 
Not at all important, Slightly important, Moderate important, Very important, or 
Extremely important 
To what degree has the delay in elective in-patient epilepsy monitoring affected you? 
            Not at all, Very mildly, Mildly, Moderately, or Severely  
How informed are you about COVID-19? 
            Not at all informed, Slightly informed, Moderately informed, Very informed, or 
 Extremely informed 
How informed are you about how COVID-19 will affect your hospital stay? 
            Not at all informed, Slightly informed, Moderately informed, Very informed, or 





APPENDIX E.  Follow-up survey 
 
Patient education of seizure disorder 
 
How would you describe your understanding of your seizure disorder? 
            Very poor, Poor, Fair, Good, or Excellent 
How would you describe your understanding of your prognosis and adjusted treatment 
regimen? 
            Very poor, Poor, Fair, Good, or Excellent 
What questions do you still have? 
  
EMU quality control 
 
How comfortable do you feel speaking with healthcare providers and asking questions? 
On a scale of 1 to 10, with 1 being not comfortable at all and 10 being extremely  
 comfortable.   
Do you feel that you have control over your treatment plan? 
On a scale of 1 to 10, with 1 being not at all in control and 10 being completely in           
  control.  
What positive experiences did you have during this hospital admission? 
What negative experiences did you have during this hospital admission? 
Was this process worth it? 
On a scale of 1 to 10, with 1 being not at all and 10 being extremely worth it. 
  
COVID 
How concerned are you about receiving in-person medical care during the pandemic? 
On a scale of 1 to 10, with 1 being not concerned at all and 10 being extremely     
 concerned.  
What are your major concerns? 
How well did BIDMC minimize your risk of exposure to COVID? 
            Far below standards, below standards, Meets standards, Above standards, or Far 
 above standards 
How did the limitation on visitors impact your past admission to the EMU? 
On a scale of 1 to 10, with 1 being not at all and 10 being extremely impactful. 
How important to you is the increase in personal protective equipment of patients and 
providers? 
            Not at all important, Slightly important, Moderate important, Very important, or 
 Extremely important 
To what degree has the delay in elective in-patient epilepsy monitoring affected you? 
            Not at all, Very mildly, Mildly, Moderately, or Severely  
How informed were you about how COVID-19 will affect your hospital stay? 
            Not at all informed, Slightly informed, Moderately informed, Very informed, or 
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